Pier Paolo Piccaluga

By Pier Paolo Piccaluga, Stefania Paolini, Francesca Bonifazi, Giuseppe Bandini, Giuseppe Visani and Sebastian Giebel

Part of the book: New Advances in Stem Cell Transplantation

By Anna Gazzola, Alessandro Broccoli, Vittorio Stefoni and Pier Paolo Piccaluga

Part of the book: Innovations in Stem Cell Transplantation

By Pier Paolo Piccaluga, Stefania Paolini, Giovanna Meloni, Giuseppe Visani and Felicetto Ferrara

Part of the book: Innovations in Stem Cell Transplantation

By Pier Paolo Piccaluga

Part of the book: Peripheral T-cell Lymphomas

By Pier Paolo Piccaluga

Part of the book: Acute Leukemias

By Erica Diani, Davide Gibellini and Pier Paolo Piccaluga

Part of the book: Malaria

By Pier Paolo Piccaluga and Wanyonyi Ignatius

Malaria is an acute febrile illness that is caused by infection with Plasmodium spp. parasites. Malaria is a serious illness and sometimes it may be fatal resulting in mortality and morbidity. The clinical picture painted in patients with malarial infection occurs following the release of the merozoites into the bloodstream following the rupture of infected red cells. In the infection with the P. falciparum, the commonest form affecting humans, all stages of red cells are infected making the infection quite severe as compared to infection with other species which infects the old and young red cells only which contributes to a small percentage of red cells. In this chapter, the Authors review the current knowledge about Malaria epidemiology, pathogenesis and anatomic pathology. The diverse clinical pictures as well as the association with genetic conditions and diseases are discussed.

Part of the book: Malaria

By Pier Paolo Piccaluga

Part of the book: Advances in Hematological Malignancies

By Nicholas Anthony Othieno-Abinya and Pier Paolo Piccaluga

The advent of tyrosine kinase inhibitors (TKIs) has transformed CML from a fatal disease into a manageable chronic condition. This review aims to provide a comprehensive overview of the current therapeutic landscape for CML and discuss the unique challenges in the treatment of CML, particularly in resource-limited settings such as Kenya. The introduction of TKIs marked a paradigm shift in the management of CML. Imatinib, the first-generation TKI, demonstrated remarkable efficacy in inducing durable cytogenetic and molecular responses, establishing it as the gold standard for first-line therapy. However, resistance and intolerance to imatinib necessitated the development of new drugs as dasatinib, nilotinib, bosutinib, ponatinib, and asciminib have been introduced. Despite these advancements, significant challenges persist in the management of CML in developing countries like Kenya. The high cost of TKIs, limited healthcare infrastructure, and scarcity of specialised medical professionals are formidable barriers to optimal treatment. In conclusion, the therapeutic landscape of CML has evolved dramatically with the advent of TKIs and novel agents, offering hope for achieving long-term disease control and even treatment-free remission. However, the disparity in access to these therapies between developed and developing countries underscores the need for global health strategies to ensure equitable treatment.

Part of the book: Advances in Hematological Malignancies

By Maryam Etebari, Mohsen Navari and Pier Paolo Piccaluga

Follicular helper T-cell Lymphomas (FH-TCL) refers to a group of peripheral T-cell lymphomas (PTCLs) that phenotypically shows T follicular helper cell markers. These tumors morphologically are heterogeneous and correspond to angioimmunoblastic T-cell lymphoma (AITL), follicular helper T-cell lymphoma, follicular type (FTCL), and a subset of nodal PTCL/NOS with TFH phenotype (FH-TCL/NOS), all included in a same chapter since 2017 in the two latest Editions of the WHO Classification. Though these three groups of PTCLs share some biological and clinicopathological features, their correlation at transcriptome level is still uncertain. While some authors suggest that FTCLs might actually be a part of AITL spectrum, some consider them solely to share common origin. In order to improve our understanding of the matter, we studied the correlation of these lymphomas based on their global gene expression profiles. Our results suggest that FTCLs, similar to FH-TCL/NOS, show a molecular profile distinct from AITL. Furthermore, we suggest that differences in molecular signatures of FTCL and AILT might be related to differences in their master transcription regulators. We conclude that our data support the most recent WHO classification, maintaining distinct the three groups of FH-TCL though under a same chapter.

Part of the book: Advances in Hematological Malignancies